Profile data is unavailable for this security.
About the company
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
- Revenue in USD (TTM)6.88m
- Net income in USD-141.43m
- Incorporated1983
- Employees160.00
- LocationCelldex Therapeutics Inc53 Frontage Road, Suite 220HAMPTON 08827United StatesUSA
- Phone+1 (908) 200-7500
- Fax+1 (302) 655-5049
- Websitehttps://celldex.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.53bn | 988.00 | -- | -- | -- | 2.73 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 2.55bn | 352.00 | 22.93 | 4.66 | 21.39 | 4.86 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Neogen Corp | 929.24m | 1.57m | 2.60bn | 2.64k | 1,667.13 | 0.8276 | 22.09 | 2.80 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.67bn | 226.00 | -- | 15.32 | -- | 34.46 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.81bn | 160.00 | -- | 5.54 | -- | 407.55 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Arcellx Inc | 110.32m | -70.69m | 2.81bn | 130.00 | -- | 5.68 | -- | 25.45 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.82bn | 597.00 | -- | 6.50 | -- | 3.88 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Merus NV | 43.95m | -154.94m | 2.84bn | 172.00 | -- | 7.85 | -- | 64.58 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.89bn | 50.00 | -- | 5.52 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Azenta Inc | 641.02m | -17.37m | 2.98bn | 3.50k | -- | 1.22 | 42.62 | 4.65 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 3.01bn | 497.00 | -- | 8.12 | -- | 12.07 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 3.03bn | 525.00 | -- | 16.38 | -- | 16.66 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Apogee Therapeutics Inc | 0.00 | -83.99m | 3.06bn | 91.00 | -- | 6.89 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.08bn | 517.00 | -- | 19.06 | -- | 7.71 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Dec 2023 | 6.48m | 10.05% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 6.07m | 9.43% |
Eventide Asset Management LLCas of 31 Dec 2023 | 3.63m | 5.64% |
RTW Investments LPas of 31 Dec 2023 | 3.46m | 5.38% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.31m | 5.14% |
Polar Capital LLPas of 31 Dec 2023 | 3.14m | 4.87% |
Kynam Capital Management LPas of 31 Dec 2023 | 3.01m | 4.67% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.95m | 4.59% |
Point72 Asset Management LPas of 31 Dec 2023 | 2.76m | 4.28% |
Bellevue Asset Management AGas of 31 Dec 2023 | 2.42m | 3.75% |